To much rambling on the other board. Curious your
Post# of 110
I do have a question for you on the prospect of a BO. Is there a valuation of the tech for the other cell lines or would the company reserve those vaccines and attempt to get those through phase 2/3 and sell each individually?? This is unique in the vaccine impacts so many different solid tumors.